KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Halozyme Therapeutics (HALO) over the last 16 years, with Q3 2025 value amounting to -$7.2 million.

  • Halozyme Therapeutics' Change in Accured Expenses rose 6909.67% to -$7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.5 million, marking a year-over-year increase of 27793.56%. This contributed to the annual value of $47.0 million for FY2024, which is 47456.56% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Change in Accured Expenses stood at -$7.2 million, which was up 6909.67% from -$29.7 million recorded in Q2 2025.
  • Halozyme Therapeutics' Change in Accured Expenses' 5-year high stood at $50.2 million during Q4 2024, with a 5-year trough of -$29.7 million in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' median Change in Accured Expenses value was -$2.0 million (recorded in 2023), while the average stood at $1.7 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Change in Accured Expenses plummeted by 300766.87% in 2023, and later soared by 62944.4% in 2024.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Change in Accured Expenses stood at $3.5 million in 2021, then crashed by 90.61% to $326000.0 in 2022, then plummeted by 3007.67% to -$9.5 million in 2023, then surged by 629.44% to $50.2 million in 2024, then tumbled by 114.27% to -$7.2 million in 2025.
  • Its Change in Accured Expenses was -$7.2 million in Q3 2025, compared to -$29.7 million in Q2 2025 and $9.2 million in Q1 2025.